id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-338346-e3fk6gz2	Oliveros, Estefania	Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach	2020-08-14		.txt	text/plain	2482	158	46	24 The Council on Hypertension of the European Society of Cardiology has highlighted the lack of evidence supporting the harmful effects of ACE inhibitors and ARBs in the context of the pandemic COVID-19 outbreak. 25 The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual antihypertensive therapy because there is no clinical or scientific evidence to suggest that treatment with ACE inhibitors or ARBs should be discontinued because of COVID-19 infection. American Heart Association statement said there were no experimental or clinical data demonstrating beneficial or adverse outcomes with background use of ACE inhibitors, ARBs or other RAAS antagonists among COVID-19 patients with a history of cardiovascular disease treated with such agents. Patients with a left ventricular assist device (LVAD) or who have had a heart transplant are a particularly challenging group to manage in the current pandemic. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic	./cache/cord-338346-e3fk6gz2.txt	./txt/cord-338346-e3fk6gz2.txt